Vanguard Group Inc Aeglea Bio Therapeutics, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.11 - $0.46 $148,449 - $620,790	-1,349,544 Reduced 67.56%	648,053 $291,000
Q4 2022 Feb 10, 2023	BUY	$0.35 - $1.54 $38,570 - $169,709	110,201 Added 5.84%	1,997,597 $898,000
Q3 2022 Nov 14, 2022	SELL	$0.38 - $0.81 $23,032 - $49,096	-60,613 Reduced 3.11%	1,887,396 $993,000
Q2 2022 Aug 12, 2022	SELL	$0.5 - $2.66 $84,657 - $450,375	-169,314 Reduced 8.0%	1,948,009 $984,000
Q1 2022 May 13, 2022	SELL	$1.87 - $4.77 $6,174 - $15,750	-3,302 Reduced 0.16%	2,117,323 $4.87 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $8.42 $41,527 - $99,903	11,865 Added 0.56%	2,120,625 $10.1 Million
Q3 2021 Nov 12, 2021	BUY	$6.03 - $7.95 $69,911 - $92,172	11,594 Added 0.55%	2,108,760 $16.8 Million
Q2 2021 Aug 13, 2021	BUY	$6.32 - $8.38 $13.3 Million - $17.6 Million	2,097,166 New	2,097,166 $14.6 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.